News report or editorial covering the phase 2 retatrutide trial results showing approximately 24% mean body weight loss—the highest weight reduction reported for any pharmacological agent at the time of publication. Contextualizes this result within the evolving obesity drug landscape and discusses its implications for future obesity treatment and the development of even more effective agents.
Harris, Emily